↓ Skip to main content

CD74–NRG1 Fusions in Lung Adenocarcinoma

Overview of attention for article published in Cancer Discovery, April 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
2 news outlets
twitter
7 X users
patent
7 patents

Citations

dimensions_citation
239 Dimensions

Readers on

mendeley
175 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CD74–NRG1 Fusions in Lung Adenocarcinoma
Published in
Cancer Discovery, April 2014
DOI 10.1158/2159-8290.cd-13-0633
Pubmed ID
Authors

Lynnette Fernandez-Cuesta, Dennis Plenker, Hirotaka Osada, Ruping Sun, Roopika Menon, Frauke Leenders, Sandra Ortiz-Cuaran, Martin Peifer, Marc Bos, Juliane Daßler, Florian Malchers, Jakob Schöttle, Wenzel Vogel, Ilona Dahmen, Mirjam Koker, Roland T. Ullrich, Gavin M. Wright, Prudence A. Russell, Zoe Wainer, Benjamin Solomon, Elisabeth Brambilla, Hélène Nagy-Mignotte, Denis Moro-Sibilot, Christian G. Brambilla, Sylvie Lantuejoul, Janine Altmüller, Christian Becker, Peter Nürnberg, Johannes M. Heuckmann, Erich Stoelben, Iver Petersen, Joachim H. Clement, Jörg Sänger, Lucia A. Muscarella, Annamaria la Torre, Vito M. Fazio, Idoya Lahortiga, Timothy Perera, Souichi Ogata, Marc Parade, Dirk Brehmer, Martin Vingron, Lukas C. Heukamp, Reinhard Buettner, Thomas Zander, Jürgen Wolf, Sven Perner, Sascha Ansén, Stefan A. Haas, Yasushi Yatabe, Roman K. Thomas

Abstract

We discovered a novel somatic gene fusion, CD74-NRG1, by transcriptome sequencing of 25 lung adenocarcinomas of never smokers. By screening 102 lung adenocarcinomas negative for known oncogenic alterations, we found four additional fusion-positive tumors, all of which were of the invasive mucinous subtype. Mechanistically, CD74-NRG1 leads to extracellular expression of the EGF-like domain of NRG1 III-β3, thereby providing the ligand for ERBB2-ERBB3 receptor complexes. Accordingly, ERBB2 and ERBB3 expression was high in the index case, and expression of phospho-ERBB3 was specifically found in tumors bearing the fusion (P < 0.0001). Ectopic expression of CD74-NRG1 in lung cancer cell lines expressing ERBB2 and ERBB3 activated ERBB3 and the PI3K-AKT pathway, and led to increased colony formation in soft agar. Thus, CD74-NRG1 gene fusions are activating genomic alterations in invasive mucinous adenocarcinomas and may offer a therapeutic opportunity for a lung tumor subtype with, so far, no effective treatment.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 175 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
United States 1 <1%
Germany 1 <1%
Unknown 172 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 49 28%
Student > Ph. D. Student 27 15%
Other 15 9%
Student > Master 13 7%
Student > Doctoral Student 10 6%
Other 26 15%
Unknown 35 20%
Readers by discipline Count As %
Medicine and Dentistry 48 27%
Biochemistry, Genetics and Molecular Biology 39 22%
Agricultural and Biological Sciences 34 19%
Chemistry 4 2%
Pharmacology, Toxicology and Pharmaceutical Science 3 2%
Other 7 4%
Unknown 40 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2023.
All research outputs
#1,254,835
of 23,202,641 outputs
Outputs from Cancer Discovery
#611
of 3,722 outputs
Outputs of similar age
#13,299
of 226,511 outputs
Outputs of similar age from Cancer Discovery
#5
of 52 outputs
Altmetric has tracked 23,202,641 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,722 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.9. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,511 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.